Shares of Trevi Therapeutics, Inc. (TRVI) have gained 6.5% over the past four weeks to close the last trading session at $10.64, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $21.5 indicates a potential upside of 102.1%.The mean estimate comprises 12 short-term price targets with a standard deviation of $3.26. While the lowest estimate of $16.00 indicates a 50.4% increase from ...

Core Insights - Trevi Therapeutics, Inc. is developing Haduvio™ (oral nalbuphine ER) for chronic cough treatment in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC) [2][3] Company Overview - Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on Haduvio™, which is the first investigational therapy to demonstrate a statistically significant reduction in cough frequency in clinical trials for both IPF chronic cough and RCC [2] - Haduvio acts on the cough reflex arc as a kappa agonist and mu antagonist (KAMA), targeting opioid receptors involved in chronic cough control [2] Industry Context - Chronic cough in patients with IPF and non-IPF ILD represents a significant unmet medical need, with approximately 150,000 U.S. patients with IPF, two-thirds of whom experience uncontrolled chronic cough [3] - There are around 228,000 U.S. patients with non-IPF ILD, with 50-60% suffering from uncontrolled chronic cough, leading to severe impacts on morbidity and mortality [3] - RCC affects approximately 2-3 million U.S. patients and is characterized by a persistent cough lasting over 8 weeks despite treatment for underlying conditions, with significant physical, psychological, and social impacts [4]

Core Insights - Biotech shares experienced significant movements in after-hours trading, with Sarepta Therapeutics leading due to anticipated trial data and other companies benefiting from recent clinical and regulatory updates [1] Company Summaries - Sarepta Therapeutics Inc. (SRPT) saw a surge of 9.65% to $23.17, driven by anticipation for a webcast on January 26, 2026, where three-year topline results from its Phase 3 trial of ELEVIDYS for Duchenne muscular dystrophy will be presented, potentially pivotal for its gene therapy program [2] - Fractyl Health, Inc. (GUTS) increased by 7.66% to $2.25, indicating speculative interest despite no new company news, suggesting momentum-driven trading [3] - Greenwich LifeSciences, Inc. (GLSI) advanced 2.08% to $26.00 following FDA approval of the first commercial lot of GP2 vials for the FLAMINGO-01 trial, marking a significant step in its commercialization efforts with the potential to prepare approximately 200,000 doses [4] - Anebulo Pharmaceuticals, Inc. (ANEB) rose 8.41% to $1.16, attracting buyers despite no new updates, reflecting investor interest [5] - OmniAb, Inc. (OABI) gained 4.59% to $2.05, similar to Anebulo, indicating broader investor interest in the biotech sector without fresh news [6] - Trevi Therapeutics, Inc. (TRVI) added 3.40% to $10.33 after publishing results from its Phase 2b CORAL trial in a peer-reviewed journal, enhancing credibility and investor enthusiasm [7] - AEON Biopharma, Inc. (AEON) edged up 1.80% to $1.13, confirming a meeting with the FDA and securing shareholder approval for financing transactions, simplifying its capital structure ahead of a second PIPE financing closing expected around January 27, 2026 [8]

Core Insights - Trevi Therapeutics announced positive results from the Phase 2b CORAL trial for oral nalbuphine ER, showing a statistically significant reduction in 24-hour objective cough frequency in patients with idiopathic pulmonary fibrosis (IPF) [1][2] - Over 60% of patients treated with nalbuphine ER achieved at least a 50% reduction in cough frequency at Week 6 compared to baseline [1] - The trial results were published in the Journal of the American Medical Association (JAMA), validating the findings and emphasizing the unmet need for chronic cough treatment in IPF patients [2] Company Overview - Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Haduvio (oral nalbuphine ER) for chronic cough in patients with IPF, non-IPF interstitial lung disease, and refractory chronic cough [6] - Haduvio is the first investigational therapy to demonstrate a statistically significant reduction in cough frequency in clinical trials for both IPF chronic cough and refractory chronic cough [6] Trial Details - The Phase 2b CORAL trial was a double-blind, randomized, placebo-controlled study involving 165 patients, evaluating three doses of nalbuphine ER (27 mg, 54 mg, and 108 mg) over a 6-week period [5] - The primary efficacy endpoint was the relative change in 24-hour cough frequency, measured objectively, at the end of Week 6 compared to baseline [5] Safety Profile - The safety results of the CORAL trial were consistent with the known safety profile of nalbuphine ER, with discontinuation rates due to adverse events being similar between nalbuphine ER (5.6%) and placebo (5.0%) groups [3] - Common adverse events included nausea, vomiting, constipation, dizziness, headache, fatigue, somnolence, and dry mouth [3] Industry Context - Chronic cough in patients with IPF represents a significant unmet medical need, with approximately 150,000 patients in the U.S. and two-thirds experiencing uncontrolled chronic cough [4] - The impact of chronic cough is profound, with patients potentially coughing up to 1,500 times per day, leading to increased morbidity and a decline in quality of life [4]

Core Insights - Trevi Therapeutics is advancing its investigational therapy Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) [1][4][5] Company Updates - The company has scheduled an End-of-Phase 2 meeting with the FDA in the first quarter of 2026 to discuss the clinical development and regulatory pathway for Haduvio [1][7] - A Phase 2b trial for RCC is planned to initiate in the first half of 2026 [1][7] - David Hastings, the new Chief Financial Officer, will attend the LifeSci Partners Corporate Access Event alongside senior management [7] Product Information - Haduvio (oral nalbuphine ER) is the first investigational therapy to show a statistically significant reduction in cough frequency in clinical trials for both IPF chronic cough and RCC [4] - The therapy acts on the cough reflex arc as a kappa agonist and mu antagonist, targeting opioid receptors involved in chronic cough control [4] Market Need - There are approximately 150,000 U.S. patients with IPF, with two-thirds experiencing uncontrolled chronic cough [5] - About 228,000 U.S. patients have non-IPF ILD, with 50-60% suffering from uncontrolled chronic cough [5] - RCC affects an estimated 2-3 million U.S. patients and is characterized by a persistent cough lasting over 8 weeks despite treatment for underlying conditions [6]

Leadership Change - Trevi Therapeutics, Inc. appointed David Hastings as Chief Financial Officer, effective January 6, 2026, marking a significant leadership change as the company transitions into a more advanced development stage [2] - Hastings brings 25 years of financial leadership experience in public life sciences companies and has helped raise $2 billion in equity and debt financing, aligning with Trevi's growth strategy [2] Clinical Development - Trevi is preparing to request an End-of-Phase 2 meeting with the FDA in Q4 2025 for its lead program targeting chronic cough associated with idiopathic pulmonary fibrosis (IPF), having completed key Phase 2 work [3] - The company expects to initiate a Phase 3 program in the first half of 2026, reinforcing its transition into this critical phase of development [3] Safety and Efficacy Studies - The ongoing Phase 1 TIDAL study in IPF patients has shown no safety signals, and a completed drug-drug interaction study confirmed that nalbuphine ER can be safely co-administered with standard antifibrotic therapies [4] - Trevi has presented topline Phase 2b CORAL data, enhancing clinical and investor visibility [4] Financial Position - As of the end of Q3 2025, Trevi Therapeutics reported a cash balance of $194.9 million, positioning the company well to capitalize on its clinical momentum [5] - The company is focused on developing Haduvio, an oral extended-release therapy for chronic cough across IPF, Non-IPF ILD, and refractory chronic cough [5]

Market Overview - The article discusses the potential for strong market momentum to continue into 2026, with a focus on identifying the next wave of multibagger stocks [1][2] - Chris Toomey from Morgan Stanley expects a solid year for markets in 2026, driven by secular tailwinds, improving earnings visibility, supportive fiscal and monetary policies, and a revival of market enthusiasm due to deregulation and increased M&A activity [3][4] Investment Strategy - Toomey emphasizes the importance of market leadership broadening, suggesting that previously overlooked sectors may present new investment opportunities, moving beyond the dominance of mega-cap technology stocks [5] - The methodology for selecting the best multibagger stocks includes filtering for stocks with a market capitalization over $500 million, at least 150% returns over the past year, and a minimum of 50% upside potential [7] Company Highlights CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Market Cap: $696.38 million, with a 1-year price return of 263.72% and an upside potential of 58.20% [9] - 90% of analysts are bullish on CTMX, with a median price target of $6.50, indicating a healthy upside potential [10] - H.C. Wainwright has reiterated a "Buy" rating with a $10.00 price target, anticipating critical data for the CX-2051 therapy in colorectal cancer [11] - The firm outlines performance benchmarks for CX-2051, categorizing potential outcomes into "slam dunk," "bull," and "bear" scenarios based on expected response rates and survival metrics [12] - The company is progressing with its CX-2051 program, with enrollment nearing 100 patients ahead of a planned Phase 1 update in Q1 2026 [13][14] Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Market Cap: $1.59 billion, with a 1-year price return of 169.11% and an upside potential of 73.40% [15] - The appointment of David Hastings as CFO is seen as a strategic move to support the company's transition into advanced development stages [16] - Trevi is preparing for a Phase 3 program for Haduvio in chronic cough associated with idiopathic pulmonary fibrosis (IPF), with an End-of-Phase 2 meeting with the FDA expected in Q4 2025 [17] - Ongoing studies have shown no safety signals, and the company has a cash balance of $194.9 million as of Q3 2025, positioning it well for future clinical developments [18][19]

Core Insights - CFOs are increasingly using terms like "uncertainty" and "unprecedented" to describe the current economic landscape, reflecting a sense of fatigue with ongoing unpredictability [1] - The focus for CFOs is on taking actionable steps to build resilience in the face of uncertainty, rather than succumbing to inaction [1][2] - There is a significant shift in resource allocation towards technology functions within companies, although uncertainty remains regarding AI's full impact on financial performance [3][4] Financial Strategies - Key questions for CFOs include improving liquidity, operational efficiency, and determining essential versus non-essential investments [2] - Despite uncertainty, it is crucial for companies to review long-standing strategies and seize competitive opportunities, particularly in AI investments [2] - The recommended focus for AI efforts is 80% on productivity for growth and 20% on productivity for efficiency, emphasizing better time utilization rather than headcount reduction [5] Future Outlook - McKinsey's research suggests that by 2030, profound changes in work processes will necessitate a reorganization of value creation and activities [4] - Managing uncertainty effectively involves planning for both positive and negative scenarios, highlighting the importance of a cross-functional approach within the C-suite [6] - The global economic outlook indicates that AI-driven investments are supporting better-than-expected growth, despite underlying demand remaining soft [9]

Core Insights - Trevi Therapeutics, Inc. has appointed David Hastings as the new Chief Financial Officer effective January 6, 2026, to lead financial strategy and support the company's growth phase [1][2][3] Company Overview - Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on developing Haduvio™ (oral nalbuphine ER) for treating chronic cough associated with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC) [1][4] - Haduvio is the first investigational therapy to demonstrate a statistically significant reduction in cough frequency in clinical trials for both IPF chronic cough and RCC patients [4] Market Need - There are approximately 150,000 patients with IPF in the U.S., with two-thirds experiencing uncontrolled chronic cough, and around 228,000 patients with non-IPF ILD, with 50-60% also suffering from uncontrolled chronic cough [5] - RCC affects an estimated 2-3 million patients in the U.S. and is characterized by a persistent cough lasting over 8 weeks despite treatment for underlying conditions [6] Leadership Experience - David Hastings brings over 25 years of financial leadership in life sciences and biopharmaceuticals, having raised over $2 billion in equity and debt financing throughout his career [2] - His previous roles include CFO at Arbutus and Incyte, where he managed financial operations during significant transitions and commercialization phases [2][3] Strategic Importance - Hastings' experience is deemed critical as Trevi transitions into Phase 3 development for Haduvio, with a focus on advancing the treatment for chronic cough [3] - The company is positioned with statistically significant data across target indications, limited competition, and a strong cash position, which are expected to enhance long-term value for patients and shareholders [3]

Core Viewpoint - Trevi Therapeutics (TRVI) is being initiated with a "Buy" rating due to its advancement in getting its lead program into phase 3 testing [2]. Company Overview - Trevi Therapeutics is positioned favorably in the biotech sector, with its lead program already progressing to phase 3 testing, indicating a strong potential for future growth and value creation [2]. Analyst Background - The analysis is provided by Terry Chrisomalis, who has extensive experience in the biotech sector and runs the Biotech Analysis Central service, which offers in-depth analysis and a model portfolio of biotech stocks [2].